Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) hit a new 52-week high during trading on Thursday . The stock traded as high as $29.15 and last traded at $28.75, with a volume of 124,402 shares traded. The stock had previously closed at $28.36.

Several analysts have recently issued reports on TBPH shares. Evercore ISI started coverage on shares of Theravance Biopharma in a research report on Monday, August 29th. They issued a “buy” rating and a $41.00 price target on the stock. Leerink Swann started coverage on shares of Theravance Biopharma in a research report on Thursday, May 12th. They issued an “outperform” rating and a $26.00 price target on the stock. Zacks Investment Research raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Tuesday, July 12th. Guggenheim started coverage on shares of Theravance Biopharma in a research report on Monday, June 20th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Bank of America Corp. lowered shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $32.00.

The firm’s market cap is $1.38 billion. The firm has a 50 day moving average price of $26.01 and a 200-day moving average price of $21.78.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.01. On average, analysts anticipate that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current fiscal year.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 49,122 shares of Theravance Biopharma stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the completion of the transaction, the executive vice president now directly owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $27.99, for a total transaction of $125,703.09. Following the transaction, the senior vice president now directly owns 188,293 shares of the company’s stock, valued at $5,270,321.07. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.